期刊
NATURE CHEMICAL BIOLOGY
卷 12, 期 7, 页码 511-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.2082
关键词
-
资金
- NIGMS [R01-GM56322]
- Cancer Prevention and Research Institute of Texas (CPRIT) [RP150596]
- Harold C. Simmons Cancer Center Startup Awards
- Disease Oriented Clinical Scholar (DOCS) award
- Damon Runyon Clinical Investigator award [CI-68-13]
- Welch Foundation [I-1879]
CD437 is a retinoid-like small molecule that selectively induces apoptosis in cancer cells, but not in normal cells, through an unknown mechanism. We used a forward-genetic strategy to discover mutations in POLA1 that coincide with CD437 resistance (POLA1(R)). Introduction of one of these mutations into cancer cells by CRISPR-Cas9 genome editing conferred CD437 resistance, demonstrating causality. POLA1 encodes DNA polymerase alpha, the enzyme responsible for initiating DNA synthesis during the S phase of the cell cycle. CD437 inhibits DNA replication in cells and recombinant POLA1 activity in vitro. Both effects are abrogated by the identified POLA1 mutations, supporting POLA1 as the direct antitumor target of CD437. In addition, we detected an increase in the total fluorescence intensity and anisotropy of CD437 in the presence of increasing concentrations of POLA1 that is consistent with a direct binding interaction. The discovery of POLA1 as the direct anticancer target for CD437 has the potential to catalyze the development of CD437 into an anticancer therapeutic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据